{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:16:15Z","timestamp":1788671775351,"version":"build-2803163510"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmorwd.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Real World Data and Digital Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.esmorw.2026.100685","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:52:24Z","timestamp":1771235544000},"page":"100685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4409-4341","authenticated-orcid":false,"given":"J.","family":"Bosveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.B.M.","family":"Suelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2251-0104","authenticated-orcid":false,"given":"M.D.","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-2147","authenticated-orcid":false,"given":"K.K.H.","family":"Aben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7982","authenticated-orcid":false,"given":"R.P.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-1543","authenticated-orcid":false,"given":"A.","family":"Richters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmorw.2026.100685_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100685_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.eururo.2025.02.005","article-title":"Why we need more attention on bladder cancer: establishing policy recommendations for health care professionals and politicians","volume":"87","author":"Ecke","year":"2025","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100685_bib3","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2025 guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.esmorw.2026.100685_bib4","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.esmorw.2026.100685_bib5","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmorw.2026.100685_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1532421","article-title":"Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)","volume":"15","author":"Zacchi","year":"2025","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100685_bib8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.21873\/anticanres.16922","article-title":"Comparison of oncological outcomes of pembrolizumab as second-line therapy and maintenance avelumab therapy in advanced urothelial carcinoma after platinum-based chemotherapy","volume":"44","author":"Shindo","year":"2024","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.esmorw.2026.100685_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmorw.2026.100685_bib10","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10147-024-02573-5","article-title":"Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort","volume":"29","author":"Miyake","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmorw.2026.100685_bib12","series-title":"Wijziging Regeling zorgverzekering i.v.m. in- en uitstroom enkele sluismiddelen","year":"2021"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100685_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047256","article-title":"Prospective Bladder Cancer Infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts\u2019 study ProBCI","volume":"11","author":"Richters","year":"2021","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.esmorw.2026.100685_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100685_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/pst.2004","article-title":"Restricted mean survival time as a summary measure of time-to-event outcome","volume":"19","author":"Hasegawa","year":"2020","journal-title":"Pharm Stat"},{"issue":"4","key":"10.1016\/j.esmorw.2026.100685_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.euf.2021.08.009","article-title":"Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: a contemporary Dutch nationwide cohort study","volume":"8","author":"Richters","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.esmorw.2026.100685_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100685_bib19","doi-asserted-by":"crossref","first-page":"594.e29","DOI":"10.1016\/j.urolonc.2025.05.014","article-title":"Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy","volume":"43","author":"Moon","year":"2025","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.esmorw.2026.100685_bib20","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1007\/s12094-025-03950-w","article-title":"Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study)","volume":"27","author":"Sotelo","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"10.1016\/j.esmorw.2026.100685_bib22","doi-asserted-by":"crossref","first-page":"328.e17","DOI":"10.1016\/j.urolonc.2024.10.026","article-title":"Guidelines versus real-world data in metastatic bladder cancer: a population-based study on first-line chemotherapy treatment patterns","volume":"43","author":"Slotman","year":"2025","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.esmorw.2026.100685_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmorw.2026.100685_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"}],"container-title":["ESMO Real World Data and Digital Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949820126000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:53:34Z","timestamp":1788670414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949820126000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":20,"alternative-id":["S2949820126000044"],"URL":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100685","relation":{},"ISSN":["2949-8201"],"issn-type":[{"value":"2949-8201","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world comparison of avelumab maintenance versus pembrolizumab at progression after first-line platinum-based chemotherapy in metastatic urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Real World Data and Digital Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmorw.2026.100685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100685"}}